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Epidermal growth factor receptor (EGFR) is overexpressed in ovarian carcinomas, with direct or indirect activation of EGFR able to
trigger tumour growth. We demonstrate significant activation of both signal transducer and activator of transcription (STAT)3 and its
upstream activator Janus kinase (JAK)2, in high-grade ovarian carcinomas compared with normal ovaries and benign tumours. The
association between STAT3 activation and migratory phenotype of ovarian cancer cells was investigated by EGF-induced epithelial–
mesenchymal transition (EMT) in OVCA 433 and SKOV3 ovarian cancer cell lines. Ligand activation of EGFR induced a fibroblast-like
morphology and migratory phenotype, consistent with the upregulation of mesenchyme-associated N-cadherin, vimentin and nuclear
translocation of b-catenin. This occurred concomitantly with activation of the downstream JAK2/STAT3 pathway. Both cell lines
expressed interleukin-6 receptor (IL-6R), and treatment with EGF within 1h resulted in a several-fold enhancement of mRNA
expression of IL-6. Consistent with that, EGF treatment of both OVCA 433 and SKOV3 cell lines resulted in enhanced IL-6
production in the serum-free medium. Exogenous addition of IL-6 to OVCA 433 cells stimulated STAT3 activation and enhanced
migration. Blocking antibodies against IL-6R inhibited IL-6 production and EGF- and IL-6-induced migration. Specific inhibition of
STAT3 activation by JAK2-specific inhibitor AG490 blocked STAT3 phosphorylation, cell motility, induction of N-cadherin and
vimentin expression and IL6 production. These data suggest that the activated status of STAT3 in high-grade ovarian carcinomas may
occur directly through activation of EGFR or IL-6R or indirectly through induction of IL-6R signalling. Such activation of STAT3
suggests a rationale for a combination of anti-STAT3 and EGFR/IL-6R therapy to suppress the peritoneal spread of ovarian cancer.
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Despite considerable progress achieved in the management of
gynaecological cancers, cure of epithelial ovarian cancer still
remains evasive, with an overall 5-year mortality of 70%. The
peritoneal spread of ovarian cancer to surrounding organs within
the abdomen relies on the movement of cancer cells, which are
regulated in an autocrine or a paracrine manner by growth factors
and cytokines present in the peritoneal tumour fluid (Puiffe et al,
2007). In this context, the contribution of epithelial–mesenchymal
transition (EMT) by endogenous or exogenous growth factors may
be vital to initiate and sustain abdominal cell motility of tumour
cells. Recently, some studies have reported EMT-like processes in
ovarian cancer cells in response to stimuli present in the ascites
(Theriault et al, 2007), but the exact role of the process in the
context of cancer progression still remains elusive.
We have previously shown that ovarian surface epithelial cells
(Ahmed et al, 2006) and ovarian cancer cells undergo EMT in
response to EGF (Ahmed et al, 2007; Lim et al, 2007). Elevated
expression of epidermal growth factor receptor (EGFR) and its
ligand are common in many epithelial cancers including ovarian
cancer (Psyrri et al, 2005). Epidermal growth factor/EGFR
autocrine and paracrine processes driving tumour cell prolifera-
tion has formed the basis for chemotherapeutic drug targeting of
EGFR in some cancers (Blank et al, 2005). Activated EGFR triggers
diverse signalling pathways in tumour cells (Ahmed et al, 2006;
Yarden and Shilo, 2007). We have recently shown that EGF-
induced EMT in ovarian surface epithelial cells is associated with
matrix remodelling through matrix metalloproteases and is
mediated by the classical extracellular signal-regulated kinase
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s(ERK) and integrin-linked kinase (ILK)/glycogen synthase kinase
3b pathways (Ahmed et al, 2006). Integrin-linked kinase pathway
is also responsible for EMT in ovarian cancer induced by
endothelin, and combined targeting of endothelin receptor and
EGF receptors has shown enhanced antitumour activity in ovarian
cancers (Bagnato and Rosano `, 2007; Rosano ` et al, 2007). Beside
endothelin, bone morphogenetic proteins induce EMT-like
changes in ovarian cancer cells (Theriault et al, 2007). In addition,
VEGF and lysophosphatidic acid, which are present in high
abundance in the ascites and serum of ovarian cancer patients,
induces invasiveness in cultured ovarian cancer cell lines (Ahmed
et al, 2006; Wang et al, 2006). In a recent study, we have shown
that ascites from ovarian cancer patients induce distinct changes
associated with invasiveness in ovarian cancer cells (Ahmed et al,
2005). However, whether this facilitation of invasiveness is
EMT-dependent still remains elusive.
Janus kinase (JAK)/signal transducer and activator of transcrip-
tion (STAT) signalling is required for diverse processes during
embryogenesis (Teng et al, 2004), and activation of this pathway
has been associated with cancers (Chen et al, 2007). This pathway
is activated when an extracellular ligand binds to its receptor
resulting in the activation of JAK(s) and phosphorylation of
specific tyrosine residues on the receptor. Signal transducer and
activator of transcription proteins are recruited to the receptor by
binding to the phosphorylated tyrosine residues through the SRC
homology domain 2 in the STAT proteins. Signal transducer and
activator of transcriptions are then phosphorylated by JAK, after
which they dimerise and shuttle to the nucleus where they function
as a transcription factor. Notably, interleukin (IL)-6, oncostatin M
and leukaemia inhibitory factor (LIF) signal through receptors that
share a common GP130 receptor subunit, which signals through
JAK2 and STAT3 (Carbia-Nagashima and Arzt, 2004). Signal
transducer and activator of transcription3 activation can also
occur through EGFR either by direct ligand activation or by
indirect ligand-independent transactivation, and such activation
have been shown to mediate cancer cell proliferation and
carcinogenesis (Sriuranpong et al, 2003; Chan et al, 2004).
In humans, STATs have a unique expression pattern and
distinct physiological functions (Levy and Darnell, 2002). Signal
transducer and activator of transcription3 has been shown to
maintain cancer cell proliferation, as inhibition of STAT3 led to
inhibition of growth in several cancer cell lines (Chen et al, 2007),
including ovarian cancer (Silver et al, 2004). However, naturally
occurring mutations in STAT3 protein resulting in its constitutive
activation have not been identified, suggesting that aberrant
growth factor signalling, frequent in cancer, may regulate the
constitutive activation of STAT3.
Recent evidence indicates a role for STAT3 in cell motility.
In zebrafish embryos undergoing gastrulation, STAT3 is essential for
the migration of sheets of cells (Yamashita et al, 2002). STAT3 is also
required for mouse gastrulation, which represents a classical EMT
model in embryonic development (Takeda et al,1 9 9 7 ) .M o u s e
keratinocytes conditionally depleted of STAT3 show defects in
wound healing (Sano et al, 1999). Activation of JAK/STAT pathway
in the Drosophila ovary causes the ‘extra cells’ to become invasive,
while the migration of a subset of epithelial follicular cells called the
‘border cells’ is dependent on STAT expression (Silver and Montell,
2001). As initiation of the human ovarian cancer postulated to
originate from the ovarian surface epithelium with subsequent
exfoliation of tumour cells in the peritoneum somewhat resembles
the situation in the Drosophila ovary, it is not surprising that several
of the genes that control Drosophila epithelial follicle cell migration
are homologous to genes implicated in the progression of ovarian
cancer (Montell, 2003).
In addition to the migratory role of STAT3 described above,
recent studies have reported an association between STAT3 and
EMT (Lo et al, 2007). This is mediated through E-cadherin
repressors, the zinc-finger transcription factor Snail and estrogen-
regulated zinc transporters LIV-1 in breast tumours (Taylor et al,
2004). Recently, gastrin has been reported to induce EMT in colon
cancer through the JAK2/STAT3 pathway (Ferrand et al, 2004),
while gastrin-releasing peptides have been shown to transactivate
EGFR in pancreatic cancer (Thomas et al, 2005). In addition,
oncostatin M has been shown to induce EMT in tubular epithelial
cells through GP130-mediated activation of JAK2/STAT3 pathway
(Nightingale et al, 2004), indicating that this pathway may be
critical for cytokine and growth factor-mediated responses
regulating EMT biology in fibrogenesis and cancer.
In the light of the evidence supporting the activated status of
STAT3 in ovarian carcinomas and the role of STAT3 in cell
motility and EMT, this study sought to directly examine the role of
this pathway in EGF-induced EMT in ovarian cancer cells.
Although tyrosine kinase receptors, such as EGFR, are capable of
activating STAT3, the incidence of STAT3 activation by inflam-
matory cytokines (such IL-6) in cooperation with EGFR is
common among some tumours (Badache and Hynes, 2001). Thus,
it is possible that additional pathways other than EGFR may
participate in the activation of STAT3 to induce EMT.
To investigate that, we analysed the activation status of JAK2/
STAT3 in ovarian carcinoma specimens and correlated that to
STAT3 activation in two ovarian cancer cell lines directly by EGFR
or indirectly through IL-6R activation. We studied the association
between the increased levels of STAT3 activation and high-grade
ovarian carcinomas, consistent with a role for STAT3 in the motile
phenotype of ovarian cancer cells in response to direct activation
by EGFR or indirectly through IL-6R. In addition, we report that
the JAK2/STAT3 pathway is required to sustain EGF-induced
EMT-associated phenotypes in ovarian cancer cells, indicating that
in EGF-driven ovarian tumours JAK2/STAT3 signalling may be
critical in regulating metastasis.
MATERIALS and METHODS
Cell lines
The human epithelial ovarian cancer lines OVCA 433 and SKOV3
were obtained from Dr Robert Bast, MD Anderson Centre,
Houston, USA and have been described previously (Ahmed et al,
2003). Cell lines were grown as monolayers in 25 or 75cm
2 flasks
(Nunclon, Roskilde, Denmark) in complete growth medium
consisting of 50% medium 199 (Sigma-Aldrich, Sydney, Australia)
and 50% MCDB105 (Sigma-Aldrich) supplemented with 10% (v/v)
heat inactivated fetal bovine serum and 2mM glutamine (Invitrogen
Corporation, Melbourne, Australia) in the presence of 371C with
5% CO2.
Antibodies and reagents
Monoclonal and polyclonal antibodies against phosphorylated
(P)-ERK1/2, total (T)-ERK1/2, (P)-JAK2, T-JAK2, P-STAT3 (Tyr
705) and T-STAT3 were obtained from Cell Signalling Technology
(Beverly, MA, USA). Monoclonal antibodies against vimentin and
N-cadherin were obtained from Zymed Laboratories (San
Francisco, CA, USA). Polyclonal antibody against b-catenin was
obtained from Sigma-Aldrich and anti-human IL-6R neutralising
antibody was from R&D Systems (Minneapolis, MN, USA). The
secondary antibodies were purchased from Chemicon Inter-
national (Temecula, CA, USA) and Molecular Probes (Eugene,
OR, USA). Epidermal growth factor and AG490 were obtained
from Chemicon International and Calbiochem (San Diego, CA,
USA), respectively.
Tissues
The study was approved by the Research and Human Ethics
Committee (HEC no. 02/30) of The Royal Women’s Hospital,
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sMelbourne, Australia. Ovarian cancer patients with serous,
mucinous, endometrioid, clear cell carcinoma and mixed subtypes
were included in the study. The histopathological diagnosis and
tumour grades were determined by staff pathologists as part of the
clinical diagnosis. Histological grading of ovarian carcinoma was
determined by the method described by Silverberg (2000). Normal
ovaries were removed from patients undergoing surgery as a result
of suspicious ultrasound images, palpable abdominal masses and/
or family history. Archival tissues were obtained from the
Department of Pathology, Royal Women’s Hospital, from women
who presented for surgery after the provision of a participant
information statement and with informed consent. The mean age
of healthy volunteers and women presenting with benign and
borderline tumours was 57 years. The mean age of women with
grades 1, 2 and 3 cancer was 58 years.
Description of women included in the JAK2/STAT3 study
With few exceptions common tissues were used for JAK2, STAT3
and P-STAT3 expression. A total of 58 women were included in the
study. Among these tissues nine were from normal women, ten in
each group were from women with benign, borderline, grades 1
and 2 tumours, respectively and nine were from grade 3/4 patients.
Among the grade 1 patients, 80% had stage 1 disease, while the rest
20% had stages 2 and 3. On the other hand, 20–30% of grade 2
patients had stage 1 cancer, while 70–80% had stage 3/4. Similarly,
80–90% of grade 3 patients were diagnosed at stage 3/4, while
10–20% had stages 1 or 2 diseases.
A limited number of normal, benign, borderline, grades 1, 2 and
3/4 tissues (n¼14) of serous, mucinous and clear cell subtype were
evaluated for P-JAK2 status.
Immunohistochemical analysis on ovarian tissues was per-
formed as described previously (Ahmed et al, 2002a,b, 2003).
Briefly, paraffin sections were cut at 4mm thickness, mounted on
silane-coated slides and incubated overnight at 371C. Sections were
washed with water after two changes of xylene and three changes
of ethanol. Antigen retrieval was performed using citrate buffer
(pH 6.0), and sections were held in Tris-buffered saline.
Endogenous peroxidase activity was removed using 3% hydrogen
peroxide in methanol. The sections were incubated for 1h in
primary antibody diluted 1/200 in 1% BSA in Tris buffer (100mM,
pH 7.6). Antibody binding was amplified using biotin and
streptavidin HRP (Chemicon International) for 15min each, and
the complex was visualised using diaminobenzidine (DAB). Nuclei
were lightly stained with Mayer’s haematoxylin. Non-immune
rabbit serum was used as a control. The specificity of the
antibodies was also evaluated by western blot in ovarian cancer
cell lysates. In all cases right molecular weight bands were
observed.
Sections were assessed microscopically for positive DAB
staining. Two observers (NA and CR) independently evaluated
the immunostaining results and the degree of staining was scored
in a blind manner. The concordance ratio was 495% in each case.
Differences in opinion were resolved by re-evaluating the sections
and in some cases by reaching a consensus with the assistance of a
third evaluator. Four sections were assessed per tissue and tissue
and cellular distribution of staining was determined. For each
specimen, the positive staining extent was scored in five grades,
namely: 0 (p10%), 1 (X11–25%), 2 (X26–50%), 3 (X51–75%),
4( X76–90%) and 5 (X90–100%).
SDS–PAGE and western blot analyses
Western blot and SDS–PAGE were performed on cell lysates by the
methods described previously (Ahmed et al, 2003). Protein loading
was monitored by stripping the membrane with Re-Blot solution
(Chemicon International) and re-probing the membrane
with b-actin primary antibody (Sigma-Aldrich). Densitometry
(ODmm
 2) was performed using the Multi Gauge V2.3 computer
program.
Preparation of serum-free medium and IL-6 sandwich
ELISA
Cells were grown in 25cm
2 flask in standard growth medium until
80–90% confluence was attained. Cells were washed in serum-free
medium three times and incubated in the same medium for 24h.
The medium was collected by centrifugation, and protein content
in the medium was estimated using a commercial protein assay kit
with BSA standards according to the manufacturer’s instructions
(Pierce, Rockford, IL, USA). The IL-6 sandwich ELISA was
performed using a sandwich ELISA kit (Biosource International,
Camarillo, CA, USA) according to the manufacturer’s instruction.
All data were normalised for total protein and expressed as
pgmg
 1 of protein.
Indirect immunofluorescence
Immunofluorescence analysis of N-cadherin, b-catenin and
vimentin was performed as described previously (Lebret et al,
2007). Images were captured by the photo multiplier tube using the
Leica TCS SP2 laser, and were viewed on an HP workstation and
the Leica microsystems TCS SP2 software.
Cell migration assay
Cell migration assay was performed as described previously
(Lebret et al, 2007). Photos were taken of the scratches at 0 and
14h using a Sony Digital Camera. The width of the scratches was
measured at each time point and quantified using Microsoft Excel
computer program.
RNA extraction and RT–PCR
Total cellular RNA was extracted and analysed by real-time
RT–PCR as previously described (Trenerry et al, 2007). Primers
(Supplementary Information) were designed using Primer Express
software package version 3.0 (Applied Biosystems, Foster city, CA,
USA) from gene sequences obtained from GenBank and checked
for specificity using nucleotide–nucleotide Blast search. The
efficacy of cyclophilin as endogenous controls was examined
using the Equation 2
 DCt.
Statistical analysis
The significance of the extent of immunohistochemical staining
between normal, benign, borderline, grades 1, 2 and 3 ovarian
tumours was determined by the non-parametric w
2 contingency
test (Ahmed et al, 2002a,b). Student’s t-test was also used for the
statistical analyses of migration assay and western blot data. Data
are presented as mean±standard error of the mean (s.e.m.). Each
experiment was repeated at least three times in triplicate. Statistical
analysis for RT–PCR was performed using GraphPad Prism 4.1
(GraphPad Software, San Diego, CA, USA) (Trenerry et al, 2007).
Means were compared using two-way ANOVA and any significant
differences were analysed using a Bonferroni post hoc test. Data are
presented as mean±s.e.m. A probability level of Po0.05 was
adopted throughout to determine statistical significance unless
otherwise stated.
RESULTS
JAK2/STAT3 status in ovarian carcinomas
We compared the expression and activation status of JAK2 and
STAT3 in a range of benign, borderline, and malignant ovarian
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stumours and normal ovaries, using immunohistochemistry
(Figure 1). Expression of JAK2 was observed in the epithelial cells
and the stroma of all samples. Both cytoplasmic and membrane-
associated JAK2 expression was significantly different between the
normal ovaries and the tumour groups (Figure 1A and C) (Table 1).
In contrast, activated JAK2, as detected using P-JAK2-specific
antibodies, was observed only in the epithelium of grades 1 and 3
tumours and was not present in the normal, benign and borderline
tumours (Figure 1B and D). Signal transducer and activator of
transcription3 was expressed in both epithelial and stromal cells,
with no significant difference observed between normal ovaries,
benign, borderline and malignant tumours (Figure 1E and G).
However, there was a significant difference in the levels of
activated STAT3 between the normal, benign, borderline and
histological grades of tumours (Table 1), with latter showing the
highest levels of expression (Figure 1F and H). P-STAT3 was
observed in both the nucleus and cytoplasm. None of the tissues
showed any positive staining with the control IgG antibodies.
EGF-induced changes in the expression and localisation of
N-cadherin, vimentin and b-catenin and also increased
motility of ovarian cancer cells
The relationships between the observed activation of the
JAK2/STAT3 pathway in ovarian specimens were correlated with
EGF-induced phenotypic changes in OVCA 433 and SKOV3
ovarian carcinoma cell lines. These cells typically grow as epithelial
cobblestone-like monolayers but show a fibroblast-like morphol-
ogy typical of mesenchymal cells in the presence of EGF (Lim et al,
2007). Epidermal growth factor-treatment of OVCA 433 and
SKOV3 cells lead to a significant increase in both N-cadherin and
vimentin expression within 24h (Figure 2A and B) (Colomiere
et al, 2008). However, EGF-induced EMT had no significant effect
on b-catenin expression in either cancer cell line (data not shown).
Immunofluorescence studies revealed cell–cell junction locali-
sation of N-cadherin in control untreated cells. Within 24h of EGF
treatment, concurrent with the enhanced expression of
N-cadherin, some granular cytoplasmic localisation of the protein
was observed in addition to the cell–cell junction localisation
(Figure 2C). In contrast, the localisation of vimentin in both
control and EGF-treated cells remained filamentous (Figure 2D).
However, EGF treatment resulted in the translocation of b-catenin
from the cytoplasm and cell junctions to discrete regions of the
nucleus in certain population of cells (Figure 2E), consistent with
the activation of the b-catenin-mediated pathways in response to
EGF-associated EMT events (Polette et al, 2007).
Consistent with the changes in the expression and localisation of
N-cadherin, vimentin and b-catenin, EGF also induced a motile
phenotype in ovarian cancer cells as evaluated by wound-healing
assay in serum-free medium (Ahmed et al, 2006; Lim et al, 2007).
In the absence of EGF, 43% wound closure was observed in OVCA
433 cells after 14h compared to 75% wound closure after EGF
treatment under similar conditions, with essentially the same
results obtained with SKOV3 cells (Figure 2F and G) (Colomiere
et al, 2008). These results suggest that EGF enhances the EMT-
associated motile phenotype of ovarian cancer cells.
Activation of JAK2/STAT3 pathways induced by EGF
correlates with EMT
Epidermal growth factor is known to activate several signalling
pathways (Yip et al, 2007), but direct activation of JAK2/STAT3 is
rarely observed (Badache and Hynes, 2001). We investigate the
potential involvement of this pathway in EGF-induced EMT.
Epidermal growth factor stimulation lead to a significant induction
of P-JAK2, which levels at 45min (Figure 3A and B), and P-STAT3
peaking at 1h in OVCA 433 and 4h in SKOV3 cells (Figure 3C and D)
relative to the expression of T-JAK2 and T-STAT3 (Colomiere et al,
2008). In OVCA 433 cells, active STAT3 showed double bands
representative of a- and b-isoforms of the enzyme. The threshold
activation of STAT3 in some ovarian cancer cell lines depended on
the endogenous level of phosphorylated STAT3. OVCA 433 cells
showed relatively higher level of endogenous active STAT3; hence,
increment of active STAT3 in the presence of EGF was much less
than SKOV3 cells. Moreover, in many cases the expression of
phosphorylated proteins resulted in background noise, which in
many experiments was difficult to avoid. This may be because of
the low amount of phosphorylated proteins present in the cell
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Figure 1 Activation of JAK2 and STAT3 in ovarian carcinomas. Expression of JAK2, P-JAK2, STAT3 and P-STAT3 in archival normal ovaries and high-
grade ovarian tumours using the immunoperoxidase method, as discussed in the Materials and Methods. (A) Normal ovary, arrows indicating continuous
expression of JAK2 in the epithelium. (B) No expression of P-JAK2 was evident in the stroma or epithelium of the normal ovary. (C and D) Scattered
cytoplasmic and membrane staining of JAK2 and P-JAK2 (indicated by arrows) in a serous high-grade ovarian tumour. Same tissues were used to evaluate the
expression of JAK2 and P-JAK2. (E and F) Nuclear and cytoplasmic expression of STAT3 and P-STAT3 (indicated by arrows) in the epithelium and stroma
of normal ovaries. (G and H) Epithelial staining of P-STAT3 (nuclear and cytoplasmic) in an endometrioid high-grade ovarian carcinoma. Magnification  40,
scale¼50mm.
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slysates. No immunostaining was observed with control IgG
antibodies.
EGF induces the expression of IL-6 and LIF in ovarian
cancer cell lines
To evaluate whether EGF would induce a secondary stimulus that
may act in concert to stimulate the JAK2/STAT3 pathway, we used
real-time RT–PCR to quantify the expression of IL-6 and LIF as
well as their respective receptors. The levels of IL-6 mRNA were
significantly increased following EGF stimulation of both OVCA
433 (5.2-fold, Po0.05) and SKOV3 (126-fold increase, Po0.05)
cells (Figure 4). Leukaemia inhibitory factor mRNA was also
increased, albeit to a lesser extent (OVCA 433, 2.1-fold, Po0.05;
SKOV3, 4.0-fold). Importantly, the genes encoding the relevant
receptor chains were expressed in each cell type: IL-6Ra and GP130
constituting the IL-6 receptor complex and LIFRa and GP130,
constituting the LIF receptor complex. Indeed, levels of the IL-6Ra
and GP130 mRNAs were modestly, but significantly increased
following 1h stimulation with EGF in SKOV3 cells (2.5- and 2.4-
fold, respectively). These data support the idea that the observed
EGF-induced activation of JAK2 and STAT3 may have resulted, at
least in part, by the induction of IL-6 and LIF and subsequent
autocrine activation by the common GP130 signal-transducing
chains.
EGF enhances the production of IL-6 in ovarian cancer cell
lines
To determine if mRNA increase in IL-6R expression in response to
EGF treatment has any affect on the production of IL-6 in ovarian
cancer cell lines, we used IL-6 sandwich ELISA to quantify the
amount of IL-6 secreted by OVCA 433 and SKOV3 cell lines in
response to EGF. Both OVCA 433 and SKOV3 cell lines produced
IL-6 endogenously but, in the presence of EGF, the production of
IL-6 was increased (Po0.05) in the serum-free medium of both
ovarian cancer cell lines (Figure 4B), consistent with the mRNA
enhancement of IL-6 and IL-6Ra on the cells (Figure 4A).
Inhibition of EGF-induced IL-6 production and migration
by neutralising IL-6R antibodies
We tested the functionality of the IL-6R complex by studying the
response of OVCA 433 cells to IL-6. Strong activation of STAT3
was evident in OVCA 433 cells within 30min, whereas no
activation of classical ERK1/2 pathway was observed (Figure 5A
and B). To evaluate the role of EGF-induced IL-6 synthesis on the
migration in OVCA 433 cells, a wound-healing assay was
performed in the presence of neutralising IL-6R antibody after
treatment with IL-6 (20ngml
 1) or EGF (10ngml
 1). Both IL-6
and EGF induced migration in OVCA 433 cells to a similar extent
(Figure 5C). Neutralising IL-6R antibody (20mgml
 1) inhibited
IL-6-induced migration to the level of control untreated cells and
had a partial effect on the EGF-induced migration (45% wound
closure compared to 60% in EGF-treated and 38% in control
untreated cells) under similar conditions (Figure 5C). Consistent
with that, EGF-induced IL-6 was partially inhibited with the same
concentration of the antibody in OVCA 433 cells (Figure 5D) but
completely inhibited in SKOV3 cells (data not shown). These
results suggest that signalling from the IL-6R by secreted or cell-
bound IL-6 produced in an autocrine manner in response to EGF
affects the EGF-induced IL-6 secretion and migratory phenotype of
ovarian cancer cells. These results suggest that the suppression of
IL-6 secretion may have a significant inhibitory effect on the
EGF-induced migration of OVCA 433 cells.
Inhibition of the JAK2/STAT3 pathway does not affect
EGF-induced morphology but blocks cell motility, EMT-
induced N-cadherin and vimentin expression and IL-6
production
To confirm that the EGF-induced EMT is dependent on the
downstream activation of JAK2/STAT3 from the IL-6R, we
determined the effects of a specific JAK2 inhibitor (AG490) on
the morphology and functional responses of cells treated with EGF
for 24h. Treatment of EGF-induced OVCA 433 cells with AG 490
(100mM) for 1h resulted in the inhibition of STAT3 activation but
there was no change in the total STAT3 expression (Figure 6A).
Table 1 The expression of P-STAT3, T-STAT3, P-JAK2 and T-JAK2 in normal ovaries, benign, borderline and histological grades of ovarian tumours
Antigen
analysed
Normal
ovaries
Benign
tumours
Borderline
tumours
Grade 1
tumours
Grade 2
tumours
Grade 3
tumours
Statistical
analysis
P-STAT3 0 (1) 0 (2) 1 (1) 0 (3) 0 (2) 1 (3) w
2¼32.74
1 (4) 1 (5) 2 (3) 1 (4) 1 (5) 2 (4) df¼20, P¼0.03
2 (1) 2 (1) 3 (6) 2 (1) 2 (3) 3 (3)
3 (2) 4 (2) 4 (1) 4 (1)
4 (1)
STAT3 0 (1) 1 (1) 1 (1) 4 (8) 3 (2) 2 (1) w
2¼28.69,
2 (2) 2 (3) 2 (2) 5 (2) 4 (4) 3 (4) df¼25, P¼0.276
3 (3) 3 (2) 3 (3) 5 (4) 4 (4)
4 (3) 4 (2) 4 (3) 5 (2)
5 (1) 5 (2)
P-JAK2 0 (4) 0 (6) 0 (2) 2 (1) — 3 (4) NA
3 (1)
T-JAK2 0 (3) 1 (1) 2 (2) 2 (1) 4 (2) 4 (1) w
2¼46.73,
2 (1) 2 (1) 3 (3) 3 (2) 5 (8) 5 (8) df¼25, P¼0.005
3 (2) 3 (3) 4 (4) 4 (4)
5 (3) 4 (3) 5 (1) 5 (3)
5 (2)
The extent of epithelial P-STAT3, T-STAT3, P-JAK2 and T-JAK2 expression was scored in a blind manner in normal ovaries and serous, endometrioid, mucinous, clear cell and
mixed ovarian carcinomas of different pathological grades. Scoring was performed as 0 (p10%), 1 (X11–25%), 2 (X26–50%), 3 (X51–75%), 4 (X76–90%) and
5( X91–100%) of immunoreactivity. Values in the parenthesis indicate number of patients evaluated for each antigen in each category. The epithelial distribution of antigens
among normal and different tumour groups was statistically analysed using w
2 calculation.
JAK2/STAT3 involvement in ovarian cancer
M Colomiere et al
138
British Journal of Cancer (2009) 100(1), 134–144 & 2009 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sOVCA 433
OVCA 433
OVCA 433
N-cadherin
Control EGF
Control EGF Control EGF
Control EGF
Control
90
80
70
60
50
40
30
20
10
0
90
100
80
70
60
50
40
30
20
10
0
%
 
o
f
 
w
o
u
n
d
 
c
l
o
s
u
r
e
%
 
o
f
 
w
o
u
n
d
 
c
l
o
s
u
r
e
Control EGF
Control EGF Control EGF
EGF
Control EGF
Control
SKOV3
SKOV3
OVCA 433 SKOV3
SKOV3
EGF Control EGF
Control EGF Control EGF
Control EGF
-Actin
Vimentin
-Actin
0.16
0.14
0.12
0.10
0.08
0.06
0.04
0.02
0.00
R
e
l
a
t
i
v
e
 
d
e
n
s
i
t
y
 
o
f
N
-
c
a
d
h
e
r
i
n
R
e
l
a
t
i
v
e
 
d
e
n
s
i
t
y
 
o
f
N
-
c
a
d
h
e
r
i
n
R
e
l
a
t
i
v
e
 
d
e
n
s
i
t
y
 
o
f
v
i
m
e
n
t
i
n
R
e
l
a
t
i
v
e
 
d
e
n
s
i
t
y
 
o
f
v
i
m
e
n
t
i
n * *
*
*
*
*
0.250
0.200
0.150
0.100
0.050
0.000
0.250
0.200
0.150
0.100
0.050
0.000
1.000
0.900
0.800
0.700
0.600
0.500
0.400
0.300
0.200
0.100
0.000
N-cadherin
-Catenin
Vimentin
0 h
14 h
i ii iii iv
viii vii vi v
Figure 2 (A and B) Enhanced expression of N-cadherin and vimentin by EGF. Cell lysates were prepared and western blot analysis was performed as
described in the Materials and Methods. Blots were stripped and re-probed with b-actin to indicate relative amounts of protein loaded. Three independent
experiments were performed and each blot is a representative of one individual experiment. Graphs are represented as the mean density of N-cadherin and
vimentin bands normalised against the mean density of b-actin band from three independent experiments (presented as relative density of individual protein).
*Po0.05 compared to control untreated cells. (C–E) Expression and localisation of N-cadherin, vimentin and b-catenin in OVCA 433 and SKOV3 cell lines in
the presence and absence of EGF. Confocal microscopy was performed as described in the Materials and Methods. Proteins were visualised by Alexa 488
fluorescent label (green) and nuclei were visualised by ethidium bromide staining (red). The image is a representative of four independent experiments.
Scale¼30mm. (F and G) Effect of EGF on the migration of OVCA 433 and SKOV3 cells. Cells were cultured on glass coverslips in either normal growth
medium (control) or EGF-treated medium (10ngml
 1). Using scratch tests over 14h, SKOV3 and OVCA 433 cells were analysed for the extent of wound
closure as described in the Materials and Methods. For each coverslip four scratches were made and the width of each scratch was measured at four different
locations at 0 and 14h time points to determine the extent of wound. Phase contrast images are representative of one independent experiment repeated three
times. The graphs represent mean % of wound closure from three independent experiments. *Po0.05 compared to control untreated cells. Scale¼300mm.
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in the inhibition of N-cadherin and vimentin expression (Figure 6B
and C) without any change in the expression of b-catenin (data not
shown).
The effect of this pharmacological inhibition of JAK2 had no
effect on the morphological phenotype of EGF-induced epithelial
cells. Within 24h in the presence of the inhibitor, the cells did not
revert to an epithelial phenotype and maintained their fibroblast-
like morphology (data not shown). In contrast, significant
inhibition in cell motility was observed within 14h (Figure 6D)
in EGF-treated cells in the presence of AG490 (100mM), indicating
that JAK2/STAT3 pathway may be involved in the EGF-induced
motility of ovarian cancer cells. AG 490 treatment of OVCA 433
cells also resulted in the inhibition of EGF-induced IL-6 secretion
(Figure 6E).
DISCUSSION
The acquisition of a motile function is correlated with a dramatic
change in the cell physiology of most epithelia. Migrating cells no
longer express epithelial characteristics and acquire mesenchymal
properties. These include a loss of epithelial-like polygonal
morphology, basal cell polarity and adhesive contacts, develop-
ment of a fibroblast-like shape, reorganisation of cytoskeleton
filaments, increased cell motility and induction of proteases for
ECM degradation requisite for migration and invasion. Such
profound changes have been reported previously as EMT, a
cellular process manifested during embryo and organ morpho-
genesis (Hay and Zuk, 1995), wound healing (Tanaka et al, 2004),
tumour progression (Theriault et al, 2007) and reproductive tract
physiology (Demir et al, 2004). Some recent studies have
implicated a role of STAT3 and EGFR in mediating EMT in cancer
cells (Lo et al, 2007). Although the role of EMT in regulating
metastasis in ovarian cancer cells is still not clear, overexpression
of EGFR and constitutively active STAT3 have been shown in
clinical specimens and ovarian cancer cell lines (Rosen et al, 2006).
This warrants exploration into the significance of EGFR-mediated
STAT3 activation in the dissemination of ovarian carcinoma. In
this study, we show that EGF regulates many of the key processes
that lead to mesenchymal transition in epithelial ovarian cancer
cells and that autocrine signalling through the IL6-R/JAK2/STAT3
pathway is associated with these events and may regulate the
metastasis of ovarian carcinoma.
We show that normal and benign ovaries lack overt JAK2
activation, which was only present in low- and high-grade ovarian
carcinomas, despite JAK2 expression in normal ovaries, benign,
borderline and histological grades of tumours. These findings
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Figure 3 Activation of JAK2 and STAT3 in response to EGF. (A–D) Expression of activated and total JAK2 and STAT3 pre- and post-EGF treatment in
OVCA 433 and SKOV3 cell lines. Cell lysates were prepared and western blot analysis was performed as described above. Experiments were performed
three times and blots are representative of one independent experiment. Graphs are represented as the sum of the mean density of P-STAT3a and
P-STATb normalised against the mean density of T-JAK2 or T-STAT3 from three independent experiments (presented as relative density of
phosphoprotein vs total protein). *Po0.05 compared to control untreated cells at 0min.
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ssuggest an important role for JAK2 activation in ovarian
tumourigenesis. Low-to-moderate STAT3 activation was present
in normal ovaries, benign and borderline tumours as well as low-
to high-grade carcinomas but the status of activated STAT3 was
significantly different between the normal, benign, borderline and
malignant groups. These findings are consistent with the previous
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Figure 4 (A) Expression of ligands and receptor chains for the IL-6R and LIFR complexes following EGF stimulation. Gene expression was quantified using
real-time PCR for each gene indicated before stimulation (open boxes) and then at 30min (grey boxes) or 60min (black boxes) following EGF stimulation of
OVCA 433 (upper panel) or SKOV3 (lower panel). Values were normalised to the expression levels of the housekeeping gene cyclophilin, and expressed as
a mean fold change from basal±s.e.m. Genes that showed a statistically significant increase in expression (Po0.05) are indicated by *. (B) Quantification of
IL-6 production by OVCA 433 and SKOV3 cells in the presence and absence of EGF. IL-6 secreted in the serum-free medium of the cell lines was measured
by using the IL-6 sandwich ELISA kit. *Po0.05 compared to control untreated cells.
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Figure 5 (A and B) Activation of STAT3 in response to IL-6 in OVCA 433 cells. Expression of P-STAT3 in response to IL-6 in OVCA 433 cell line.
OVCA 433 cells were incubated in normal growth medium (control) or medium treated with IL-6 (20ngml
 1) for 1h. Western blot analysis was performed
as described above for P-STAT3, P-ERK1/2 followed by re-probing first with T-STAT3, T-ERK1/2, respectively, followed by b-actin. (C) Effect of neutralising
IL-6R antibody on the EGF or IL-6-induced migration in OVCA433 cells. Cells were cultured on glass coverslips in either normal growth medium (control)o r
EGF-treated medium (10ngml
 1) or IL-6-treated medium (20ngml
 1) in the presence and absence of IL-6R antibody (20mgml
 1). Using scratch tests over
14h, cells were analysed for the extent of wound closure as described in the Materials and Methods. *Po0.05, compared to control untreated cells,
ycompared to cells treated with EGF or IL-6, respectively. (D) Effect of neutralising IL-6R antibody on IL-6 production in OVCA 433 cells. IL-6 production in
the serum-free medium in the presence of þ/ EGF and þ/  anti-IL-6R or control serum was measured by sandwich ELISA assay as described in the
Material and Methods. *Po0.05, compared to control untreated cells,
ycompared to cells treated with EGF.
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carcinomas than in borderline tumours, even though no expres-
sion of activated STAT3 in normal ovarian surface epithelium was
reported (Silver et al, 2004). The fact that JAK2 is only activated in
ovarian carcinomas but not in normal ovaries or benign/border-
line tumours suggests that the activation of STAT3 in normal
ovaries and benign/borderline tumours may be independent of
JAK2 activity and may depend on the intrinsic kinase activity of
non-receptor cytoplasmic kinases such as SRC (Garcia et al, 2001)
or the cytokine/growth factor stimulation of receptors with innate
kinase activity (Badache and Hynes, 2001). None the less, the
pathogenic role of JAK/STAT signalling pathway has been
documented in cancer (Chan et al, 2004), the role of JAK2/STAT3
in the pathogenesis of ovarian cancer is still unknown. Therefore,
the identification of JAK2 activation and increased STAT3
activation in ovarian carcinoma samples is a significant step
towards answering this question.
To further evaluate the role of JAK2/STAT3 in the pathogenesis of
ovarian cancer in vitro, studies were performed using SKOV3 and
OVCA 433 as model ovarian cancer cell lines. We have previously
shown that OVCA 433 and SKOV3 cell lines can be induced by EGF
to undergo EMT-like phenotype characterised by the loss of
epithelial-restricted E-cadherin and neutrophil gelatinase-associated
lipocalin expression and a gain in the expression of mesenchyme-
associated vimentin and increased motility (Lim et al, 2007). We
now show that the activation of JAK2/STAT3 may be a pre-requisite
for EGF-induced EMT in these ovarian cancer cell lines, as
pharmacological inhibition of JAK2 in ovarian cancer cells not only
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Figure 6 Effect of JAK2 inhibitor on STAT3 activation, EGF-induced N-cadherin, vimentin and cell migration. (A) Expression of P-STAT3 in OVCA 433
cells post-treatment with EGF and EGFþAG490 a specific JAK2 inhibitor. Cells were incubated in normal growth medium (control), medium treated with
EGF (10ngml
 1) or treated with EGF (10ngml
 1) and AG490 (100mM) for 1 or 4h. respectively. Western blot analysis was performed as described above
for P-STAT3 followed by re-probing with STAT3 and b-actin. *Po0.05, compared to control untreated cells and,
ycompared to cells in the presence of EGF.
Densitometry was performed as described above. (B and C) Expression of N-cadherin and vimentin 24h post EGF in the absence and presence of AG490
in OVCA 433 cells. Western blot analysis for N-cadherin and vimentin was performed as described above. *Po0.05, compared to control untreated cells,
and
ycompared to cells in the presence of EGF. (D) OVCA 433 cells were cultured on glass coverslips in either normal growth medium (control) or EGF-
treated medium (10ngml
 1) or in the presence of EGF (10ngml
 1) and AG490 (100mM). Wounding assay was performed as described above. Images are
representative of one independent experiment performed three times. Graphs represent mean % of wound closure from three independent experiments.
Scale¼300mm. *Po0.05, compared to control untreated cells, and
ycompared to cells in the presence of EGF. (E) IL-6 production in the presence and
absence of EGF and EGFþAG490 was measured as described above. *Po0.05, compared to control untreated cells, and
ycompared to cells in the
presence of EGF and AG490.
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induced EMT phenotypes. These findings highlight the potential
significance of JAK2/STAT3 signalling in the acquisition of EMT-
associated phenotypes of ovarian cancer cells, which may be vital for
cancer progression and distant metastasis.
Genetic mutation or amplification of STAT proteins has not
been identified in the pathogenesis of ovarian cancer. It has been
proposed that constitutive STAT3 activation can result from
aberrant EGFR signalling (Chan et al, 2004) and a significant
correlation between high overall levels of P-STAT3 expression and
overexpression of EGFR and HER-2/neu has been reported in
ovarian cancer specimens (Rosen et al, 2006). Moreover, as only
30% of ovarian cancers express Her-2/neu or EGFR (Rosen et al,
2006), it can be suggested that the varying degrees of P-STAT3
expression exhibited by all the ovarian tumours analysed in our
study may result due to the activation or upregulation of
alternative cytokine or growth factor receptor pathways. Moreover,
mutations in EGFR kinase domain have been shown to mediate
STAT3 activation by IL-6 production in human lung carcinomas
(Gao et al, 2007), suggesting that EGFR-like STAT3 activation can
be mediated by IL-6R or GP130 receptors in an autocrine manner.
To evaluate the secondary mediator-like response of IL-6 in
response to ligand stimulation of EGFR, both OVCA 433 and
SKOV3 cell lines were treated with EGF, and the mRNA expression
of IL-6, IL-6R, LIF, LIFR and GP130 receptor were analysed within
1h. The expression of IL-6 was significantly elevated in both
ovarian cancer cell lines. The expression of LIF was enhanced to a
lesser extent, and even though the relevant receptor expression was
observed in both the cell lines, the expression of IL-6Ra and GP130
was modestly increased in SKOV3 cells. To gain further insight
into the mechanism of EGFR-induced cross talk with IL-6R
pathway, we investigated the production of IL-6 in the serum-free
medium of both the cell lines. Both OVCA 433 and SKOV3
enhanced the production of IL-6 in response to EGF stimulation
and this enhancement was abrogated by neutralising IL-6R
antibody and AG490 JAK2 inhibitor. Consistent with this fact,
neutralising anti-IL6R partially inhibited EGF-induced migration
in OVCA 433 cells, suggesting that EGF-induced migratory
phenotype is dependent to a certain extent on the EGF-induced
expression of IL-6 in certain ovarian cancer cells. A previous study
has shown the expression of GP130 and LIFRb expression in
ovarian carcinomas (Todd et al, 2002). From that perspective,
IL-6R and GP130 family of receptors may form an extensive network
of P-STAT3 signalling systems in ovarian carcinomas. However, it
still remains to be determined if activation by EGF or somatic-
activating mutations in the kinase domain of EGFR has any effect on
the production of IL-6 or GP130 family of cytokines that can lead to
the activated status of STAT3 in ovarian carcinomas.
In summary, this study provides strong evidence that activation
of JAK2 and STAT3 directly or indirectly by autocrine induction
may be one of the mechanism(s) that leads to ovarian cells
becoming tumourigenic. A significant overall correlation between
high levels of P-STAT3, EGFR and IL-6 expression has been
reported in ovarian cancer specimens (Rosen et al, 2006). In this
study, we further show that disruption of these pathways may
result in the diminution of some of the EMT-associated
phenotypes of ovarian cancer cells. Hence, diminution in
EGFR/IL-6R/STAT3 signalling may represent novel therapeutic
targets for pharmacological intervention in the management of
ovarian cancer progression.
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